Engineering mycobacteria for vaccination and controlled human infection studies

Affiliations

¹ Spatial Immunology Unit, Laboratory of Parasitic Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
² T Lymphocyte Biology Section, Laboratory of Parasitic Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA. barberd@niaid.nih.gov.

Erin F McCaffrey et al. Nat Microbiol. 2025 Feb.

. 2025 Feb;10(2):274-276.

doi: 10.1038/s41564-024-01923-3.

¹ Spatial Immunology Unit, Laboratory of Parasitic Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
² T Lymphocyte Biology Section, Laboratory of Parasitic Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA. barberd@niaid.nih.gov.

No abstract available

Conflict of interest statement

Competing interests: The authors declare no competing interests.

1. Global Tuberculosis Report 2024 (World Health Organization, 2024); https://www.who.int/publications/i/item/9789240101531
1. Mangtani, P. et al. Clin. Infect. Dis. 58, 470–480 (2014). - DOI - PubMed
1. Darrah, P. A. et al. Nature 577, 95–102 (2020). - DOI - PubMed - PMC
1. Jackson, S. & McShane, H. in Human Challenge Studies for Vaccine Development (eds Bagnoli, F. et al.) 229–255 (Current Topics in Microbiology and Immunology, Vol. 445) (Springer, 2024).
1. Morrison, H., Jackson, S. & McShane, H. Front. Immunol. 14, 1211388 (2023). - DOI - PubMed - PMC